Ask AI
ProCE Banner Activity

DYNAMIC-III: ctDNA-Guided Escalation of Adjuvant Chemotherapy vs Standard Management in Stage III Colon Cancer

Conference Coverage
Slideset

In the phase II/III DYNAMIC-III trial, ctDNA-informed escalation of adjuvant chemotherapy treatment vs standard management following surgical resection did not reduce the risk of recurrence in people with ctDNA-positive stage III colon cancer.

Released: June 05, 2025

Expiration: December 04, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group